Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Rubius Therapeutics Inc (RUBY)

Rubius Therapeutics Inc (RUBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,669,796
  • Shares Outstanding, K 89,774
  • Annual Sales, $ 0 K
  • Annual Income, $ -167,730 K
  • 60-Month Beta 2.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.59
Trade RUBY with:

Options Overview Details

View History
  • Implied Volatility 119.17%
  • Historical Volatility 54.67%
  • IV Percentile 36%
  • IV Rank 19.19%
  • IV High 439.97% on 09/25/20
  • IV Low 43.01% on 11/04/20
  • Put/Call Vol Ratio 0.85
  • Today's Volume 24
  • Volume Avg (30-Day) 127
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 421
  • Open Int (30-Day) 772

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.55
  • Number of Estimates 5
  • High Estimate -0.51
  • Low Estimate -0.59
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -7.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.52 +0.43%
on 09/24/21
23.18 -19.76%
on 09/02/21
-2.33 (-11.13%)
since 08/24/21
3-Month
18.52 +0.43%
on 09/24/21
26.33 -29.37%
on 07/02/21
-6.82 (-26.83%)
since 06/24/21
52-Week
4.20 +342.86%
on 10/30/20
38.71 -51.95%
on 03/15/21
+13.95 (+300.00%)
since 09/24/20

Most Recent Stories

More News
Phenylketonuria Drugs Market- Demand, Trends, Share,Global Demand Analysis and Opportunity Outlook 2029

Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users,...

RARE : 95.11 (-2.45%)
PTCT : 39.29 (-0.48%)
BMRN : 78.60 (-0.88%)
FIXX : 8.64 (-0.80%)
RUBY : 18.60 (-3.63%)
SYBX : 3.17 (-0.31%)
Global Phenylketonuria Drugs Market- Analysis By Recent Trends, Development And Growth Forecast To 2027

Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users,...

RARE : 95.11 (-2.45%)
PTCT : 39.29 (-0.48%)
BMRN : 78.60 (-0.88%)
FIXX : 8.64 (-0.80%)
RUBY : 18.60 (-3.63%)
SYBX : 3.17 (-0.31%)
Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell...

RUBY : 18.60 (-3.63%)
Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

First Patient Dosed with RTX-240 in Combination with KEYTRUDA (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Patients with Advanced Solid Tumors

RUBY : 18.60 (-3.63%)
Should You Buy Rubius Therapeutics (RUBY) Ahead of Earnings?

Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

RUBY : 18.60 (-3.63%)
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates

Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.

HALO : 40.29 (-4.00%)
RUBY : 18.60 (-3.63%)
SPRB : 6.27 (-1.88%)
FSTX : 7.72 (-6.31%)
KNTE : 22.67 (-2.07%)
Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell...

RUBY : 18.60 (-3.63%)
Rubius Therapeutics to Announce Second Quarter 2021 Financial Results

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell...

RUBY : 18.60 (-3.63%)
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell...

RUBY : 18.60 (-3.63%)
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA(R) (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell...

RUBY : 18.60 (-3.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 19.87
2nd Resistance Point 19.59
1st Resistance Point 19.09
Last Price 18.60
1st Support Level 18.31
2nd Support Level 18.03
3rd Support Level 17.53

See More

52-Week High 38.71
Fibonacci 61.8% 25.53
Fibonacci 50% 21.45
Last Price 18.60
Fibonacci 38.2% 17.38
52-Week Low 4.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar